FDA approves nemolizumab for prurigo nodularis

Nemolizumab (Nemluvio) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis (PN). Efficacy was established in two randomized, double-blind, placebo-controlled trials, OLYMPIA 1 and OLYMPIA 2, which enrolled 560 adults with PN. The most common adverse reactions (incidence ≥1%) in the trials were headache, atopic dermatitis, eczema, and nummular eczema.